Finoriq research workspace
Alkermes plc. (ALKS) SEC Filings & Filing Highlights
Alkermes plc, a biopharmaceutical company, engages in the research, development. Review ALKS SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
- Company
- Alkermes plc. (ALKS)
- Ticker
- ALKS
- Market Cap
- $8.7B
- Latest Price
- $52.25
- Industry
- Biotech & Pharma
Alkermes plc. (ALKS) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Alkermes plc. (ALKS).
| Event | Form | Date |
|---|---|---|
| Alkermes ContactsAlkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe | 8-K8.01 | 2026-06-15 |
| Alkermes ContactsAlkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe | 8-K7.01 | 2026-06-15 |
| On May 20, 2026, the Company held its Annual Meeting. The final voting results for the Annual M...On May 20, 2026, the Company held its Annual Meeting. The final voting results for the Annual Meeting are as follows | 8-K5.07 | 2026-05-20 |
| On May 20, 2026, at the 2026 annual general meeting of shareholders (the “Annual Meeting”) of A...On May 20, 2026, at the 2026 annual general meeting of shareholders (the “Annual Meeting”) of Alkermes plc (the “Company”), the Company’s s... | 8-K5.02 | 2026-05-20 |
| Alkermes ContactsAlkermes Announces Positive Topline Results From REVITALYZSM Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults W... | 8-K8.01 | 2026-05-12 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.